Determination of time to onset and rate of action of insulin products: Importance and new approaches

Journal of Pharmaceutical Sciences

Volumn 102, Issue 1, 2013, Pages 271-279

  Jain, Lokesh ^a   Parks, Mary H ^a   Sahajwalla, Chandrahas ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Absorption; Bioequivalence; Comparability; Insulin; Pharmacodynamics; Pharmacokinetics; Rate of action; Regulatory science; Time to onset of action

Indexed keywords

GLUCOSE; HUMALOG 50 50; HUMALOG 75 25; HUMAN INSULIN; HUMILIN 50 50; HUMILIN 70 30; INSULIN; INSULIN ASPART; INSULIN GLULISINE; INSULIN LISPRO; ISOPHANE INSULIN; NOVOLOG 50 50; NOVOLOG 70 30; RECOMBINANT HUMAN INSULIN; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; ARTICLE; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG EFFECT; GLUCOSE BLOOD LEVEL; GLUCOSE CLAMP TECHNIQUE; HUMAN; MEAL; POSTPRANDIAL STATE;

EID: 84870707023     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23355     Document Type: Article

References (13)

1. Rafuse J. 1996. Seventy-five years later, insulin remains Canada's major medical-research coup. CMAJ 155:1306-1308.
2. US Food and Drug Administration. 1982. Human insulin receives FDA approval. FDA Drug Bull 12:18-19.
3. Holleman F, Gale EA. 2007. Nice insulins, pity about the evidence. Diabetologia 50:1783-1790.
4. Arnolds S, Rave K, Hovelmann U, Fischer A, Sert-Langeron C, Heise T. 2010. Insulin glulisine has a faster onset of action compared with insulin aspart in healthy volunteers. Exp Clin Endocrinol Diabetes 118:662-664.
5. Cernea S, Kidron M, Wohlgelernter J, Raz I. 2005. Dose-response relationship of an oral insulin spray in six patients with type 1 diabetes: A single-center, randomized, single-blind, 5-way crossover study. Clin Ther 27:1562-1570.
6. Kapitza C, Zijlstra E, Heinemann L, Castelli MC, Riley G, Heise T. 2010. Oral insulin: A comparison with subcutaneous regular human insulin in patients with type 2 diabetes. Diabetes Care 33:1288-1290.
7. Rave K, Bott S, Heinemann L, Sha S, Becker RH, Willavize SA, Heise T. 2005. Time-action profile of inhaled insulin in comparison with subcutaneously injected insulin lispro and regular human insulin. Diabetes Care 28:1077-1082.
8. Steiner S, Hompesch M, Pohl R, Simms P, Flacke F, Mohr T, Pfutzner A, Heinemann L. 2008. A novel insulin formulation with a more rapid onset of action. Diabetologia 51:1602-1606.
9. Heinemann L, Anderson JH, Jr. 2004. Measurement of insulin absorption and insulin action. Diabetes Technol Ther 6:698-718.
10. Porcellati F, Bolli GB, Fanelli CG. 2011. Pharmacokinetics and pharmacodynamics of basal insulins. Diabetes Technol Ther 13 Suppl 1:S15-S24.
11. Sanofi-Aventis U.S.LLC. 2009. Insulin glulisine recombinant (Apidra) prescribing information. Accessed May 3, 2012, at: http://products.sanofi.us/apidra/apidra.pdf.
12. Heinemamm L. 2004. Time-action profiles of insulin preparations. Mainz, Germany: Kirchheim & Company GmbH.
13. Food and Drug Administration. 2008. Guidance for industry: Diabetes mellitus: Developing drugs and therapeutic biologics for treatment and prevention. Silver Spring, Maryland: US FDA. Accessed May 3, 2012, at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM071624.pdf.